Allergan Plc (AGN) 338.21 $AGN
Mintz Levin Represents Naurex Inc. in Merger with Allergan PLC
Business Wire - 1 hr 25 mins ago
Attorneys in the Corporate & Securities Section and Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, in its merger with leading global pharmaceutical company, Allergan PLC. The merger was announced on July 26.
AGN: 338.21 (-1.29)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 124.01 (+0.14), AGN: 338.21 (-1.29), GILD: 117.02 (+3.95), JAZZ: 190.06 (-2.96), TEVA: 71.24 (-0.17), SNY: 53.91 (+0.10), REGN: 543.73 (-8.72)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 338.21 (-1.29), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17), AMAG: 63.94 (-2.29)
Aesthetics Insider: Dr. Steven Dayan Goes Inside the New Allergan With CEO Brent Saunders
GlobeNewswire - Tue Jul 28, 3:39PM CDT
The latest edition of Aesthetics Insider with Dr. Steven Dayan has launched from ModernAesthetics.tv and Bryn Mawr Communications III, LCC. In this edition, Dr. Dayan talks with Brent Saunders, CEO of Allergan about Activis' $70 billion merger with Allergan this spring. The newly combined company adopted the Allergan name last month.
AGN: 338.21 (-1.29)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 338.21 (-1.29), BIIB: 311.66 (-8.27), SHPG: 267.30 (+4.05), MYL: 57.10 (+0.75), AMGN: 172.00 (-0.74), ABBV: 71.37 (+0.14), TEVA: 71.24 (-0.17)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 338.21 (-1.29), TEVA: 71.24 (-0.17)
Stocks In Rebound Mode; Icon, Cadence Break Out
at Investor's Business Daily - Tue Jul 28, 12:36PM CDT
Stocks stepped up rebound efforts and hit fresh session highs Tuesday afternoon. The major averages have recouped more than half of Monday's steep losses amid more earnings reports and mixed economic data. The S&P 500 led the pack with a 1% gain. On...
AGN: 338.21 (-1.29), BIDU: 168.28 (+0.25), MYL: 57.10 (+0.75), CDNS: 20.94 (+0.15), TEVA: 71.24 (-0.17), ICLR: 76.44 (+1.24)
Fitch Affirms Allergan's 'BBB-' Ratings Following Generic Business Sale to Teva
Business Wire - Tue Jul 28, 10:08AM CDT
Fitch Ratings has affirmed the ratings for Allergan plc (formerly known as Actavis plc; NYSE: AGN) and its subsidiaries. The Rating Outlook is Stable.
AGN: 338.21 (-1.29)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Jul 28, 9:50AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 180.95 (-1.24), AGN: 338.21 (-1.29), PPH: 74.33 (+0.39), EIS: 55.32 (-0.14), ISRA: 33.91 (-0.06), TEVA: 71.24 (-0.17)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - Tue Jul 28, 9:46AM CDT
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 338.21 (-1.29), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17)
Allergan (AGN) Stock Gaining on Canaccord Price Target Increase
at The Street - Tue Jul 28, 9:43AM CDT
Allergan (AGN) price target was raised to $396 from $352 at Canaccord which reiterating its 'buy' rating.
AGN: 338.21 (-1.29)
Critical Alerts For Alibaba, Allergan, Yelp, JC Penney and Cliffs Natural Resources Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, AGN, YELP, JCP and CLF.
AGN: 338.21 (-1.29), JCP: 8.26 (+0.06), CLF: 2.99 (+0.02), YELP: 24.10 (-9.41), BABA: 80.67 (+0.11)
Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:18AM CDT
Allergan plc (AGN) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGN: 338.21 (-1.29), ADMS: 25.57 (-0.97)
Allergan Kicks off REFRESH AMERICA Program to Supply First Responders With Free Eye Drops
PR Newswire - Tue Jul 28, 7:00AM CDT
First responders often work in conditions that can take a toll on their eyes. Exposure to heat, smoke, wind and dust may cause Dry Eye symptoms, such as irritated and painful eyes.[1] This is part of the day-to-day environmental challenges they must endure in order to do their job--saving lives. That is why today, Allergan is announcing the REFRESH AMERICA campaign to help our nation's best perform and alleviate their discomfort from dry eye. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line between 8/1/15 - 7/31/16 will lead to donations of REFRESH® eye drops to select first responder groups nationwide. Allergan guarantees a minimum product donation with an approximate retail value of $250,000, regardless of the number of eligible products sold during the campaign period.
AGN: 338.21 (-1.29)
Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
PR Newswire - Tue Jul 28, 6:00AM CDT
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (progesterone gel) under the mutual-recognition procedure (MRP).
AGN: 338.21 (-1.29), JNP: 9.62 (-0.08)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 338.21 (-1.29), KYTH: 74.47 (-0.05)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 338.21 (-1.29), SPY: 210.44 (+1.11), IYH: 162.46 (+0.36), QQQ: 111.45 (+0.32), DIA: 177.21 (+1.10), TEVA: 71.24 (-0.17), VIS: 104.49 (+1.22)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 338.21 (-1.29), QSR: 42.93 (+0.18), F: 15.09 (+0.26), QSR.TO: 55.36 (+0.01), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17), MHFI: 100.22 (+1.82)
Mintz Levin Represents Naurex Inc. in Merger with Allergan PLC
Business Wire - 1 hr 25 mins ago
Attorneys in the Corporate & Securities Section and Life Sciences Practice of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented Naurex Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging disorders of the central nervous system, in its merger with leading global pharmaceutical company, Allergan PLC. The merger was announced on July 26.
AGN: 338.21 (-1.29)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 124.01 (+0.14), AGN: 338.21 (-1.29), GILD: 117.02 (+3.95), JAZZ: 190.06 (-2.96), TEVA: 71.24 (-0.17), SNY: 53.91 (+0.10), REGN: 543.73 (-8.72)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 338.21 (-1.29), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17), AMAG: 63.94 (-2.29)
Aesthetics Insider: Dr. Steven Dayan Goes Inside the New Allergan With CEO Brent Saunders
GlobeNewswire - Tue Jul 28, 3:39PM CDT
The latest edition of Aesthetics Insider with Dr. Steven Dayan has launched from ModernAesthetics.tv and Bryn Mawr Communications III, LCC. In this edition, Dr. Dayan talks with Brent Saunders, CEO of Allergan about Activis' $70 billion merger with Allergan this spring. The newly combined company adopted the Allergan name last month.
AGN: 338.21 (-1.29)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 338.21 (-1.29), BIIB: 311.66 (-8.27), SHPG: 267.30 (+4.05), MYL: 57.10 (+0.75), AMGN: 172.00 (-0.74), ABBV: 71.37 (+0.14), TEVA: 71.24 (-0.17)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 338.21 (-1.29), TEVA: 71.24 (-0.17)
Stocks In Rebound Mode; Icon, Cadence Break Out
at Investor's Business Daily - Tue Jul 28, 12:36PM CDT
Stocks stepped up rebound efforts and hit fresh session highs Tuesday afternoon. The major averages have recouped more than half of Monday's steep losses amid more earnings reports and mixed economic data. The S&P 500 led the pack with a 1% gain. On...
AGN: 338.21 (-1.29), BIDU: 168.28 (+0.25), MYL: 57.10 (+0.75), CDNS: 20.94 (+0.15), TEVA: 71.24 (-0.17), ICLR: 76.44 (+1.24)
Fitch Affirms Allergan's 'BBB-' Ratings Following Generic Business Sale to Teva
Business Wire - Tue Jul 28, 10:08AM CDT
Fitch Ratings has affirmed the ratings for Allergan plc (formerly known as Actavis plc; NYSE: AGN) and its subsidiaries. The Rating Outlook is Stable.
AGN: 338.21 (-1.29)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Jul 28, 9:50AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 180.95 (-1.24), AGN: 338.21 (-1.29), PPH: 74.33 (+0.39), EIS: 55.32 (-0.14), ISRA: 33.91 (-0.06), TEVA: 71.24 (-0.17)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - Tue Jul 28, 9:46AM CDT
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 338.21 (-1.29), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17)
Allergan (AGN) Stock Gaining on Canaccord Price Target Increase
at The Street - Tue Jul 28, 9:43AM CDT
Allergan (AGN) price target was raised to $396 from $352 at Canaccord which reiterating its 'buy' rating.
AGN: 338.21 (-1.29)
Critical Alerts For Alibaba, Allergan, Yelp, JC Penney and Cliffs Natural Resources Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BABA, AGN, YELP, JCP and CLF.
AGN: 338.21 (-1.29), JCP: 8.26 (+0.06), CLF: 2.99 (+0.02), YELP: 24.10 (-9.41), BABA: 80.67 (+0.11)
Allergan (AGN) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 8:18AM CDT
Allergan plc (AGN) was a big mover last session, as the company saw its shares rise over 6% on the day.
AGN: 338.21 (-1.29), ADMS: 25.57 (-0.97)
Allergan Kicks off REFRESH AMERICA Program to Supply First Responders With Free Eye Drops
PR Newswire - Tue Jul 28, 7:00AM CDT
First responders often work in conditions that can take a toll on their eyes. Exposure to heat, smoke, wind and dust may cause Dry Eye symptoms, such as irritated and painful eyes.[1] This is part of the day-to-day environmental challenges they must endure in order to do their job--saving lives. That is why today, Allergan is announcing the REFRESH AMERICA campaign to help our nation's best perform and alleviate their discomfort from dry eye. Every purchase of specially-marked packages in the REFRESH OPTIVE® product line between 8/1/15 - 7/31/16 will lead to donations of REFRESH® eye drops to select first responder groups nationwide. Allergan guarantees a minimum product donation with an approximate retail value of $250,000, regardless of the number of eligible products sold during the campaign period.
AGN: 338.21 (-1.29)
Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries
PR Newswire - Tue Jul 28, 6:00AM CDT
Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a women's health specialty pharmaceutical company, today announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (progesterone gel) under the mutual-recognition procedure (MRP).
AGN: 338.21 (-1.29), JNP: 9.62 (-0.08)
Allergan reports early termination of Hart-Scott-Rodino waiting period for pending acquisition of KYTHERA
M2 - Tue Jul 28, 5:38AM CDT
Allergan (NYSE:AGN) reported on Monday the receipt of the US Federal Trade Commission's (FTC) early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to its pending acquisition of KYTHERA Biopharmaceuticals (NasdaqGS:KYTH).
AGN: 338.21 (-1.29), KYTH: 74.47 (-0.05)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 338.21 (-1.29), SPY: 210.44 (+1.11), IYH: 162.46 (+0.36), QQQ: 111.45 (+0.32), DIA: 177.21 (+1.10), TEVA: 71.24 (-0.17), VIS: 104.49 (+1.22)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 338.21 (-1.29), QSR: 42.93 (+0.18), F: 15.09 (+0.26), QSR.TO: 55.36 (+0.01), MYL: 57.10 (+0.75), TEVA: 71.24 (-0.17), MHFI: 100.22 (+1.82)
